Ranbaxy Will Produce Internal Audits To U.S. DOJ But Warns Of Impact To Industry From "Bad Policy"
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy says it has fully cooperated with the U.S. Department of Justice investigation into company practices and will produce documents requested in a subpoena motion filed in a Maryland U.S. District Court, the company said in a response filed July 15
You may also be interested in...
Two Months On, U.S. DOJ Withdraws Motion Against Ranbaxy
MUMBAI - Two months after filing a motion to enforce subpoenas against Indian drug maker Ranbaxy, the U.S. Department of Justice has withdrawn from taking further action. "The DOJ expressed its satisfaction with the documents submitted by Ranbaxy and Parexel Consulting," a source familiar with the issue informed PharmAsia News.
Two Months On, U.S. DOJ Withdraws Motion Against Ranbaxy
MUMBAI - Two months after filing a motion to enforce subpoenas against Indian drug maker Ranbaxy, the U.S. Department of Justice has withdrawn from taking further action. "The DOJ expressed its satisfaction with the documents submitted by Ranbaxy and Parexel Consulting," a source familiar with the issue informed PharmAsia News.
Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”
MUMBAI - India's largest drug maker Ranbaxy expressed its disappointment over U.S. FDA's move to issue warning letters and import alerts against drug products manufactured at its sites in Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh